Global Respiratory Syncytial Virus Prophylaxis Industry to 2030 - Featuring Abbvie, Sobi and Sanofi Among Others -

·3 min read

DUBLIN, January 28, 2022--(BUSINESS WIRE)--The "Respiratory Syncytial Virus Prophylaxis" GlobalData report has been added to's offering.

Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus belonging to the family of Pneumoviridae. The most common clinical scenario for RSV is an upper respiratory tract infection which is typically mild and self-limiting.

However, RSV is the leading cause of lower respiratory tract infections (LRTIs) in infants, with a peak age of hospitalization between 2-3 months of age. Severe respiratory disease can manifest as bronchiolitis and pneumonia, which can progress to respiratory failure or death in rare occasions. RSV is also an important cause of hospitalizations and deaths in elderly adults. Only one marketed drug is indicated for the prevention of RSV infections, Sobi/AbbVie's monoclonal antibody (mAb) Synagis (palivizumab) for the prophylaxis of RSV in infants at a high risk of severe infection.

The publisher projects the global (8MM) RSV to experience high growth during the forecast period. There are 8 prophylactic products expected to launch in the 8MM by 2030. The launch of AstraZeneca/Sanofi's improved prophylactic mAb nirsevimab and Merck's mAb clesrovimab will be a key driver of growth, replacing Synagis as standard of care prophylaxis for high-risk infants. The launch of several vaccines for adult, maternal, and pediatric patients from Pfizer, GlaxoSmithKline, Johnson & Johnson, and Bavarian Nordic will fulfill a major unmet need, and will have a significant effect on the overall size of the RSV prophylactics market.

Companies Mentioned

  • AstraZeneca Plc

  • Abbvie Inc.

  • Sobi Inc.

  • Sanofi

  • Merck & Co

  • Pfizer Inc.

  • GlaxoSmithKline

  • Johnson & Johnson

  • Bavarian Nordic


  • Overview of RSV, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

  • Topline RSV prophylaxis market revenue from 2020-2030. Annual cost of therapy and major pipeline product sales in this forecast period are included.

  • Key topics covered include current RSV prophylaxis , unmet needs and opportunities, and the drivers and barriers affecting CHB treatment sales in the 8MM.

  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.

  • Analysis of the current and future market competition in the global RSV prophylaxis market. Insightful review of the key industry drivers, constraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

  • Develop business strategies by understanding the trends shaping and driving the global RSV prophylactic market.

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the RSV prophylaxis market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

For more information about this report visit

View source version on

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting